Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

被引:113
作者
Dreger, P
Brand, R
Milligan, D
Corradini, P
Finke, J
Deliliers, GL
Martino, R
Russell, N
van Biezen, A
Michallet, M
Niederwieser, D
机构
[1] Heidelberg Univ, Dept Med 5, D-69120 Heidelberg, Germany
[2] Allgemeines Krankenhaus St Georg, Dept Hematol, Hamburg, Germany
[3] Univ Med Ctr, Dept Med Stat, Leiden, Netherlands
[4] Birmingham Heartlands Hosp, Dept Haematol, Birmingham B9 5ST, W Midlands, England
[5] Univ Milan, Ist Nazl Tumori, Bone Marrow Transplantat Unit, I-20122 Milan, Italy
[6] Univ Freiburg, Dept Haematol & Oncol, D-7800 Freiburg, Germany
[7] Osped Maggiore, BMT Ctr, Milan, Italy
[8] Hosp Santa Creu & Sant Pau, Serv Hematol Clin, Barcelona, Spain
[9] City Hosp Nottingham, Dept Haematol, Nottingham, England
[10] Hop Edouard Herriot, Unite Greffe Cellules Souches Hematopoiet, Lyon, France
[11] Univ Leipzig, Dept Hematol & Med Oncol, D-7010 Leipzig, Germany
关键词
CLL; reduced-intensity conditioning; allogeneic stem cell transplantation; treatment-related mortality;
D O I
10.1038/sj.leu.2403745
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To elucidate whether reduced-intensity conditioning (RIC) decreases treatment-related mortality (TRM) after allogeneic stem cell transplantation (allo-SCT) for chronic lymphocytic leukemia (CLL), we retrospectively compared 73 RIC cases from a recent EBMT survey with 82 patients from the EBMT database who had undergone standard myeloablative conditioning ( MC) for CLL during the same time period. The two populations were matched by adjusting the primary risk factor, the conditioning regimen, in a series of Cox models for age, sex, donor type, remission status at transplant and analyzed for its effect on TRM, relapse incidence, event-free (EFS) and overall survival ( OS). After adjustment, a significant reduction of TRM became evident for the RIC population ( hazard ratio (HR) 0.4 (95% confidence interval 0.18-0.9); P=0.03). On the other hand, RIC was associated with an increased relapse incidence (HR 2.65 (0.98-7.12); P=0.054). There was no significant difference between RIC and MC in terms of EFS (HR 0.69 (0.38-1.25); P=0.22) and OS (HR 0.65 (0.33-1.28); P=0.21). We conclude that RIC appears to favorably influence TRM after allo-SCT for CLL. This observation, as well as possible detrimental effects of RIC on relapse risk, should be confirmed by prospective studies.
引用
收藏
页码:1029 / 1033
页数:5
相关论文
共 19 条
[1]   Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation [J].
Böttcher, S ;
Ritgen, M ;
Pott, C ;
Brüggemann, M ;
Raff, T ;
Stilgenbauer, S ;
Döhner, H ;
Dreger, P ;
Kneba, M .
LEUKEMIA, 2004, 18 (10) :1637-1645
[2]   ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia [J].
Crespo, M ;
Bosch, F ;
Villamor, N ;
Bellosillo, B ;
Colomer, D ;
Rozman, M ;
Marcé, S ;
López-Guillermo, A ;
Campo, E ;
Montserrat, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (18) :1764-1775
[3]   Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].
Damle, RN ;
Wasil, T ;
Fais, F ;
Ghiotto, F ;
Valetto, A ;
Allen, SL ;
Buchbinder, A ;
Budman, D ;
Dittmar, K ;
Kolitz, J ;
Lichtman, SM ;
Schulman, P ;
Vinciguerra, VP ;
Rai, KR ;
Ferrarini, M ;
Chiorazzi, N .
BLOOD, 1999, 94 (06) :1840-1847
[4]   Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors [J].
Diaconescu, R ;
Flowers, CR ;
Storer, B ;
Sorror, ML ;
Maris, MB ;
Maloney, DG ;
Sandmaier, BM ;
Storb, R .
BLOOD, 2004, 104 (05) :1550-1558
[5]   Genomic aberrations and survival in chronic lymphocytic leukemia. [J].
Döhner, H ;
Stilgenbauer, S ;
Benner, A ;
Leupolt, E ;
Kröber, A ;
Bullinger, L ;
Döhner, K ;
Bentz, M ;
Lichter, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916
[6]   Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia [J].
Doney, KC ;
Chauncey, T ;
Appelbaum, FR .
BONE MARROW TRANSPLANTATION, 2002, 29 (10) :817-823
[7]   Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning [J].
Dreger, P ;
Brand, R ;
Hansz, J ;
Milligan, D ;
Corradini, P ;
Finke, J ;
Deliliers, GL ;
Martino, R ;
Russell, N ;
van Biezen, A ;
Michallet, M ;
Niederwieser, D .
LEUKEMIA, 2003, 17 (05) :841-848
[8]   Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia [J].
Dreger, P ;
Montserrat, E .
LEUKEMIA, 2002, 16 (06) :985-992
[9]   Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status [J].
Esteve, J ;
Villamor, N ;
Colomer, D ;
Cervantes, F ;
Campo, E ;
Carreras, E ;
Montserrat, E .
LEUKEMIA, 2001, 15 (03) :445-451
[10]   BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients [J].
Faulkner, RD ;
Craddock, C ;
Byrne, JL ;
Mahendra, P ;
Haynes, AP ;
Prentice, HG ;
Potter, M ;
Pagliuca, A ;
Ho, A ;
Devereux, S ;
McQuaker, G ;
Mufti, G ;
Yin, JL ;
Russell, NH .
BLOOD, 2004, 103 (02) :428-434